Key Publications

Publication & Posters

Molluscum Contagiosum Publications

• Molluscum Contagiosum Background

  Molluscum Epidemiology and Quality of Life Impact

  Molluscum Pathology

  Association Between Molluscum Contagiosum and Atopic Dermatitis

• Current Management for Molluscum Contagiosum

  Current Treatment Practices for Molluscum Contagiosum

  Cantharidin Mechanism of Action

  Compounded Cantharidin for the Treatment of Molluscum Contagiosum

• Use of VP-102 for Molluscum Contagiosum

Common Warts Publications

• Common Warts Background Information

• Current Management of Common Warts

  Treatment Landscape of Common Warts

  Cantharidin Use in Common Warts

• Use of VP-102 in Common Warts*

External Genital Warts Publications

• External Genital Warts Background

  External Genital Warts Epidemiology and Quality of Life Impact

  External Genital Warts Pathology and Risk of Malignancy

• Current Management of Genital Warts

• Use of VP-102 for External Genital Warts*

Plantar Warts Publications

• Plantar Warts Background Information

• Current Management of Plantar Warts

  Treatment Landscape of Plantar Warts

  Cantharidin Use in Plantar Warts

Non-Melanoma Skin Cancer Publications

• Skin Cancer Background

  General Information on Skin Cancer

  Squamous Cell Carcinoma

  Basal Cell Carcinoma

• Current Management of Non-Melanoma Skin Cancer

  Non-Melanoma Skin Cancer

  Squamous Cell Carcinoma

  Basal Cell Carcinoma

• About LTX-315

  LTX-315 Mechanism of Action

  LTX-315 Basic/Background Research

  LTX-315 Clinical Data

• About VP-315**

  VP-315, a Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma

VP-315: An Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma presentation given at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting 

VP-315: Exploratory Analysis of a Phase 2 Multicenter Study Evaluating Local Immune Activation in the Tumor Microenvironment 12 Weeks Post VP-315, an Investigational Therapy for Basal Cell Carcinoma (BCC)

* VP-102 have not been approved by the FDA for this indication
** VP-315 is being developed for BCC and have not been approved by the FDA for this indication